

Zara, J.
09/214371

09/214371

FILE 'REGISTRY' ENTERED AT 12:14:03 ON 19 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 OCT 2005 HIGHEST RN 865529-02-8
DICTIONARY FILE UPDATES: 18 OCT 2005 HIGHEST RN 865529-02-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

L1 164 SEA FILE=REGISTRY ABB=ON PLU=ON F[MITRAS] [RHECSD] [HFY]W[E
TASF] [GQTAD] [FEL]/SQSP

FILE 'CAPLUS' ENTERED AT 12:14:03 ON 19 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 19 Oct 2005 VOL 143 ISS 17
FILE LAST UPDATED: 18 Oct 2005 (20051018/ED)

Searcher : Shears 571-272-2528

09/214371

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

L2 96 S L1
L3 16 S L2 AND (MDM# OR P53)

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 17 Dec 2004
ACCESSION NUMBER: 2004:1081081 CAPLUS
DOCUMENT NUMBER: 142:69928
TITLE: Differentially regulated hepatocellular carcinoma genes and protein and DNA arrays for use in diagnosis and drug screening
INVENTOR(S): Ren, Ee Chee; Neo, Soek Ying
PATENT ASSIGNEE(S): Agency for Science, Technology and Research, Singapore
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108964	A1	20041216	WO 2004-SG166	20040604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-475508P	P 20030604

AB The invention provides genes differentially expressed in hepatocellular carcinoma (HCC) as well as DNA and protein arrays which may be used for HCC diagnosis, to assess HCC progression or regression, or the efficacy and/or toxicity of HCC therapeutics, and/or to identify candidate compds. for HCC therapy, with high predictive accuracy.

IT 391966-46-4

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; differentially regulated hepatocellular carcinoma genes and protein and DNA arrays for use in diagnosis and drug screening)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

Searcher : Shears 571-272-2528

09/214371

ED Entered STN: 04 Nov 2004
ACCESSION NUMBER: 2004:925904 CAPLUS
DOCUMENT NUMBER: 141:393465
TITLE: Genes showing altered expression in lung cancer and their products and their use in diagnosis and treatment
INVENTOR(S): Mennerich, Detlev; Bruemmendorf, Thomas; Heiden Castanos-Velez, Esmeralda; Hermann, Klaus; Kinnemann, Henrik; Li, Xinzhong; Roepcke, Stefan; Staub, Eike; Hinzmann, Bernd; Rosenthal, Andre; Pilarsky, Christian
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 1381 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10316701	A1	20041104	DE 2003-10316701	20030409
EP 1498424	A2	20050119	EP 2004-90140	20040408
EP 1498424	A3	20050525		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			DE 2003-10316701	A 20030409

AB Genes showing altered levels of expression in human bronchial carcinoma are identified for use in the diagnosis or treatment of the disease. Expression of the gene or presence of the gene product may be used as a diagnostic marker and either the gene or its product may be a target for antineoplastic drugs. Microarray anal. identified 489 genes showing altered patterns of expression in patients with lung adenocarcinoma or squamous cell carcinoma.

IT 786732-92-1
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; genes showing altered expression in lung cancer and their products and their use in diagnosis and treatment)

L3 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Dec 2003
ACCESSION NUMBER: 2003:942764 CAPLUS
DOCUMENT NUMBER: 140:3792
TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics
INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 408 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Searcher : Shears 571-272-2528

09/214371

WO 2003091391	A2	20031106	WO 2002-XA38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003091391	A2	20031106	WO 2002-US38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2002-374547P	P 20020423
			US 2002-420784P	P 20021024
			US 2002-421043P	P 20021025
			US 2002-424680P	P 20021108
			WO 2002-US38221	A 20021112

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using a Bayesian anal.

IT **391966-46-4**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics)

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 21 Nov 2003

ACCESSION NUMBER: 2003:913286 CAPLUS

DOCUMENT NUMBER: 140:776

TITLE: Method using benzodiazepine compounds for cytoprotection through MDM2 and HDM2 inhibition

INVENTOR(S): Koblish, Holly K.; Manthey, Carl L.; Molloy, Christopher J.; Lu, Tianbao; Parks, Daniel J.; Lafrance, Luis V., III; Milkiewicz, Karen L.; Carver, Ted; Grasberger, Bruce L.

PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 75 pp.

Searcher : Shears 571-272-2528

09/214371

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095625	A2	20031120	WO 2003-US14923	20030513
WO 2003095625	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-379617P	P 20020513

OTHER SOURCE(S): MARPAT 140:776
AB The invention provides a method for protecting one or more cells from programmed cytotoxic cell death by contacting the cells with a cytoprotective amount of an MDM2 and/or HDM2 inhibitor. The cytoprotective amount of inhibitor is typically used as a pulsed administration. Useful inhibitors include a class of 1,4-benzodiazepines which act as inhibitors of MDM2-p53 interactions. The method of the invention can be employed as an adjunct to chemotherapy or radiation therapy. In addition, the methods of the invention can be employed to treat a disease or condition that involves excessive cell death.
IT 186180-20-1 393113-21-8
RL: PRP (Properties)
(unclaimed protein sequence; method using benzodiazepine compds. for cytoprotection through MDM2 and HDM2 inhibition)

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 17 Oct 2003
ACCESSION NUMBER: 2003:818235 CAPLUS
DOCUMENT NUMBER: 139:322283
TITLE: Methods for production and use of mammalian complementarity determining region mimetibodies for diagnosis and therapy of human diseases
INVENTOR(S): Heavner, George A.; Knight, David M.; Scallan, Bernard J.; Ghrayeb, John
PATENT ASSIGNEE(S): Centocor, Inc., USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084477	A2	20031016	WO 2003-US9139	20030324

Searcher : Shears 571-272-2528

09/214371

WO 2003084477 A3 20050909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG
EP 1572079 A2 20050914 EP 2003-718053 20030324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: US 2002-368791P P 20020329

WO 2003-US9139 W 20030324

AB This invention pertains to methods for production and use of mammalian complementarity determining region (CDR) mimetibodies for diagnosis and therapy of human diseases. Genetic engineering, expression, and purification of human mimetibodies containing Ig fragments (CDR, variable, framework and/or constant region) as well as a ligand binding domain are disclosed in this invention. Peptides that mimic the activity of EPO, TPO, growth hormones, G-CSF, GM-CSF, IL-1ra, leptin, CTLA4, TRAIL, TGF- α and TGF- β are the focus of this genetic engineering. The aim of the invention is use of the purified recombinant proteins for diagnosis or treatment of anemia, immune or autoimmune disease, cancer, or infectious diseases. At the time of publication, claimed sequence nos. 997 to 1109 were missing, and claimed sequence nos. 984 to 996 were not clearly identified.

IT 186180-20-1 186180-22-3 186180-23-4

186180-24-5 186180-25-6

RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Mdm/hdm antagonist peptide; methods for production and use of mammalian CDR mimetibodies for diagnosis and therapy of human diseases)

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 17 Jul 2003

ACCESSION NUMBER: 2003:545267 CAPLUS

DOCUMENT NUMBER: 139:226753

TITLE: Mixed-element capture agents: A simple strategy for the construction of synthetic, high-affinity protein capture ligands

AUTHOR(S): Bachhawat-Sikder, Kiran; Kodadek, Thomas

CORPORATE SOURCE: Center for Biomedical Inventions and the Departments of Internal Medicine and Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8573, USA

SOURCE: Journal of the American Chemical Society (2003), 125(32), 9550-9551

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Demonstration of a simple strategy to generate synthetic high-affinity

Searcher : Shears 571-272-2528

09/214371

protein capture agents of practical utility for protein-detecting microarrays. The model study highlights capture of the MBP-Mdm2 fusion protein on a solid support by a linear sequence of peptides that bind to the two individual polypeptide chains.

IT 595567-95-6

RL: ARU (Analytical role, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); ANST (Analytical study); PROC (Process)

(construction of synthetic, high-affinity protein capture ligands)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 04 Jul 2003

ACCESSION NUMBER: 2003:509384 CAPLUS

DOCUMENT NUMBER: 140:52744

TITLE: An interesting approach for cancer therapy: inhibition of the association of human double minute 2 with tumor suppressor p53

AUTHOR(S): Garcia-Echeverria, Carlos; Chene, Patrick; Blommers, Marcel J. J.; Furet, P.

CORPORATE SOURCE: Oncology Research, Novartis Pharma Inc., Basel, CH-4002, Switz.

SOURCE: Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001), Meeting Date 2000, 53-54. Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Editions EDK: Paris, Fr.

CODEN: 69EDWK; ISBN: 2-84254-048-4

DOCUMENT TYPE: Conference

LANGUAGE: English

AB As part of our drug discovery program to identify low mol. weight inhibitors of the association of hdm2 with p53, we have attempted to determine the amino acid specificities of the binding pockets of hdm2 in order to establish a pharmacophore model for this protein-protein interaction. This work has resulted in the identification of a highly potent peptide inhibitor of the p53 /hdm2 protein-protein interaction.

IT 201984-21-6 201984-98-7

RL: PAC (Pharmacological activity); BIOL (Biological study)

(low mol. wt inhibitors of the association of human double minute 2 with tumor suppressor p53 as potential cancer therapy)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 07 Feb 2003

ACCESSION NUMBER: 2003:97550 CAPLUS

DOCUMENT NUMBER: 138:164674

TITLE: Molecular markers for hepatocellular carcinoma and their use in diagnosis and therapy

INVENTOR(S): Debuschewitz, Sabine; Jobst, Juergen; Kaiser, Stephan

PATENT ASSIGNEE(S): Germany

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

Searcher : Shears 571-272-2528

09/214371

LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003010336	A2	20030206	WO 2002-EP8305	20020725
WO 2003010336	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10136273	A1	20030213	DE 2001-10136273	20010725
EP 1507871	A2	20050223	EP 2002-790191	20020725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2004011945	A2	20040205	WO 2003-EP8243	20030725
WO 2004011945	A3	20040603		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1525477	A2	20050427	EP 2003-771105	20030725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DE 2001-10136273 A 20010725				
WO 2002-EP8305 W 20020725				
WO 2003-EP8243 W 20030725				

AB The invention relates to mol. markers occurring for hepatocellular carcinoma. The invention more particularly comprises gene sequences or peptides coded thereby which can be regulated upwards or downwards for hepatic cell carcinoma (HCC) in relation to healthy, normal liver cells in the expression thereof. The invention also relates to the use of said sequences in the diagnosis and/or therapy of HCC and for screening purposes in order to identify novel active ingredients for HCC. The invention also relates to an HCC specific cluster as a unique diagnostic agent for HCC.

IT 391966-46-4

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (amino acid sequence; mol. markers for hepatocellular carcinoma)

09/214371

L3 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 15 Nov 2001
ACCESSION NUMBER: 2001:829830 CAPLUS
DOCUMENT NUMBER: 136:128583
TITLE: QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction
AUTHOR(S): Galatin, Peter S.; Abraham, Donald J.
CORPORATE SOURCE: Department of Medicinal Chemistry and Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University, Richmond, VA, 23298, USA
SOURCE: Proteins: Structure, Function, and Genetics (2001), 45(3), 169-175
CODEN: PSFGEY; ISSN: 0887-3585
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To date, a number of p53-derived peptides have been evaluated in vitro for their ability to inhibit the carcinogenic p53-mdm2 interaction. Design of second-generation nonpeptidic compds. requires the reduction of large peptide structures down to small mols. maintaining the proper spatial arrangement of key functional groups. Mol. modeling software exists that can predict and rank intermol. interactions from the p53-mdm2 complex crystal structure. Such analyses can yield a pharmacophore model suitable as a search query for a 3D chemical database to generate new lead compds. As preliminary validation of this methodol., the Hydropathic INTERactions (HINT) program has been used to generate noncovalent interaction measurements between reported peptide inhibitors and mdm2. Quant. structure-activity relationships were developed expressing peptide activity as a linear combination of hydropathic descriptors. In general, HINT measurements accurately modeled the effects of even single-atom alterations of the p53-peptide structure on activity, accounting for 70-90% of variation in exptl. inhibition consts. These results surpassed those of a recently described mol. dynamics-based approach and required significantly less computation time. In conclusion, the HINT program can be integrated into the drug design cycle for next-generation p53-mdm2 complex inhibitors with confidence in its ability to simulate this noteworthy protein-protein interaction.
IT 393113-19-4 393113-21-8 393113-22-9
393113-23-0 393113-24-1 393113-25-2
RL: PAC (Pharmacological activity); BIOL (Biological study)
(QSAR hydropathic anal. of inhibitors of p53-mdm2 interaction)
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 07 Aug 2000
ACCESSION NUMBER: 2000:537884 CAPLUS
DOCUMENT NUMBER: 133:246812
TITLE: Discovery of Potent Antagonists of the Interaction between Human Double Minute 2 and Tumor Suppressor p53
AUTHOR(S): Garcia-Echeverria, Carlos; Chene, Patrick; Blommers, Marcel J. J.; Furet, Pascal

Searcher : Shears 571-272-2528

09/214371

CORPORATE SOURCE: Oncology Research and Core Technologies, Novartis Pharma Inc., Basel, CH-4002, Switz.

SOURCE: Journal of Medicinal Chemistry (2000), 43(17), 3205-3208

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB As part of a drug discovery program to identify antagonists of the p53/hdm2 (human double minute 2) protein-protein interaction, the authors have attempted to determine the amino acid specificities of hdm2's binding pockets to establish a pharmacophore model for this protein-protein interaction. This work has resulted in the identification of highly potent peptide antagonists. Structural information has been exploited to increase the hdm2-binding affinity of short peptide motifs derived from the N-terminal domain of the human wild-type p53 protein. Combining conformational constraints as selected by mol. modeling with functional groups that are able to establish addnl. electrostatic and van der Waals interactions with the hdm2 protein, the authors have been able to increase the hdm2-binding affinity of the authors initial peptide 1700-fold. Particularly interesting is the increase in binding affinity obtained by replacing tryptophan with 6-chlorotryptophan (IC₅₀ = 314 nM vs. IC₅₀ = 5 nM, 63-fold). The new interactions identified and exptl. confirmed in this work could be directly applied to the optimization of nonpeptidic leads or incorporated into the "de novo" design of antagonists of the p53/hdm2 protein-protein interaction.

IT 201984-21-6P 201984-98-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(discovery of potent antagonists of interaction between human double minute 2 and tumor suppressor p53)

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 05 May 2000

ACCESSION NUMBER: 2000:291095 CAPLUS

DOCUMENT NUMBER: 132:329919

TITLE: Modified peptides containing an antibody Fc domain as therapeutic agents

INVENTOR(S): Feige, Ulrich; Liu, Chuan-fa; Cheetham, Janet;
Boone, Thomas Charles

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 608 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024782	A2	20000504	WO 1999-US25044	19991025
WO 2000024782	A3	20020606		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,

Searcher : Shears 571-272-2528

09/214371

CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 6660843 B1 20031209 US 1999-428082 19991022
CA 2347131 AA 20000504 CA 1999-2347131 19991025
EP 1144454 A2 20011017 EP 1999-971003 19991025
EP 1144454 A3 20020911
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT, IE, SI, LT, LV, FI, RO
BR 9914708 A 20020716 BR 1999-14708 19991025
JP 2003512011 T2 20030402 JP 2000-578351 19991025
AU 767725 B2 20031120 AU 2000-12322 19991025
NZ 510888 A 20040130 NZ 1999-510888 19991025
NZ 528882 A 20050624 NZ 1999-528882 19991025
ZA 2001002753 A 20020611 ZA 2001-2753 20010404
NO 2001001963 A 20010621 NO 2001-1963 20010420
BG 105461 A 20030430 BG 2001-105461 20010424
US 2004044188 A1 20040304 US 2003-609217 20030627
US 2004053845 A1 20040318 US 2003-632388 20030731
US 2004071712 A1 20040415 US 2003-645761 20030818
US 2005123548 A1 20050609 US 2003-645784 20030818
US 2004057953 A1 20040325 US 2003-651723 20030829
US 2004087778 A1 20040506 US 2003-653048 20030829
US 2004077022 A1 20040422 US 2003-666696 20030919
PRIORITY APPLN. INFO.: US 1998-105371P P 19981023
US 1999-428082 A 19991022
WO 1999-US25044 W 19991025
US 2000-563286 A1 20000503

AB The present invention concerns fusion of Fc domains with biol. active peptides and a process for preparing pharmaceutical agents using biol. active peptides. In this invention, pharmacol. active compds. are prepared by a process comprising: (a) selecting at least one peptide that modulates the activity of a protein of interest; and (b) preparing a pharmacol. agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, Escherichia coli coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.
IT 186180-20-1D, fusion protein with IgG1 Fc domain
186180-22-3D, fusion protein with IgG1 Fc domain
186180-23-4D, fusion protein with IgG1 Fc domain
186180-24-5D, fusion protein with IgG1 Fc domain
186180-25-6D, fusion protein with IgG1 Fc domain
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Mdm/hdm antagonist; modified peptides containing an antibody Fc domain as therapeutic agents)

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

Searcher : Shears 571-272-2528

09/214371

ED Entered STN: 20 Apr 1999
ACCESSION NUMBER: 1999:241567 CAPLUS
DOCUMENT NUMBER: 131:42875
TITLE: **p53** mediated death of cells overexpressing **MDM2** by an inhibitor of **MDM2** interaction with **p53**
AUTHOR(S): Wasylyk, Christine; Salvi, Roberto; Argentini, Manuela; Dureuil, Christine; Delumeau, Isabelle; Abecassis, Joseph; Debussche, Laurent; Wasylyk, Bohdan
CORPORATE SOURCE: Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS/INSERM/ULP, Illkirch, 67404, Fr.
SOURCE: Oncogene (1999), 18(11), 1921-1934
CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER: Stockton Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The **p53** tumor suppressor is frequently inactivated in human tumors. One form of inactivation results from overexpression of **MDM2**, that normally forms a neg. auto-regulatory loop with **p53** and inhibits its activity through complex formation. The authors have investigated whether disrupting the **MDM2-p53** complex in cells that overexpress **MDM2** is sufficient to trigger **p53** mediated cell death. The authors find that expression of a peptide homolog of **p53** that binds to **MDM2** leads to increased **p53** levels and transcriptional activity. The consequences are increased expression of the down-stream effectors **MDM2** and p21WAF1/CIP1, inhibition of colony formation, cell cycle arrest and cell death. There is also a decrease in E2F activity, that might have been due to the known phys. and functional interactions of **MDM2** with E2F1/DP1. However, this decrease is **p53** dependent, as are also colony formation, cell cycle arrest and cell death. These results show that a peptide homolog of **p53** is sufficient to induce **p53** dependent cell death in cells overexpressing **MDM2**, and support the notion that disruption of the **p53-MDM2** complex is a target for the development of therapeutic agents.
IT 186180-20-1 227200-18-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**p53-MDM2** inhibitor; **p53** mediated death of human osteosarcoma cells overexpressing **MDM2** by inhibitor of **MDM2** interaction with **p53** in relation to)
REFERENCE COUNT: 96 THERE ARE 96 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Nov 1998
ACCESSION NUMBER: 1998:709096 CAPLUS
DOCUMENT NUMBER: 129:326112
TITLE: **Mdm2** binding domain conjugates for delivery of therapeutic and diagnostic substances to cells with inefficient **mdm2-p53** degradation pathway

Searcher : Shears 571-272-2528

09/214371

INVENTOR(S): Lane, David Philip
PATENT ASSIGNEE(S): University of Dundee, UK
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847919	A1	19981029	WO 1998-GB1140	19980420
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9870642	A1	19981113	AU 1998-70642	19980420
PRIORITY APPLN. INFO.:			GB 1997-8089	A 19970422
			WO 1998-GB1140	W 19980420

AB **Mdm2** binds to **p53** in cells in which **mdm2** is not overexpressed, i.e. in cells in which **mdm2** is expressed at normal or low levels, and this interaction targets **p53** for degradation. The invention exploits this mechanism of **p53** degradation to stabilize a substance comprising a **mdm2** binding domain linked to a coupling partner in cells in which this **mdm2** mediated degradation pathway does not operate efficiently. In contrast, in normal cells expressing functional **mdm2**, the substance will tend to be unstable as it will be marked for degradation through the interaction of the endogenous **mdm2** with the **mdm2** binding domain of the substance. Accordingly, the substances can be used to deliver the coupling partner to such cells, e.g. for use in the diagnosis and/or treatment of cancer, viral infections or other conditions associated with non functional **p53** or **mdm2**.

IT 215295-80-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TIP (thioredoxin insert protein) 12/1 peptide; **mdm2** binding domain conjugates for delivery of therapeutic and diagnostic substances to cells with inefficient **mdm2-p53** degradation pathway)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Nov 1998
ACCESSION NUMBER: 1998:708953 CAPLUS
DOCUMENT NUMBER: 129:326111
TITLE: Materials and methods relating to inhibiting the interaction of **p53** and **mdm2**, and use for treatment of cancer, viral infections, or other conditions

Searcher : Shears 571-272-2528

09/214371

INVENTOR(S): Lane, David Philip
 PATENT ASSIGNEE(S): University of Dundee, UK
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847525	A1	19981029	WO 1998-GB1144	19980420
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2287344	AA	19981029	CA 1998-2287344	19980420
AU 9870644	A1	19981113	AU 1998-70644	19980420
AU 731431	B2	20010329		
EP 977580	A1	20000209	EP 1998-917411	19980420
EP 977580	B1	20030409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 236651	E	20030415	AT 1998-917411	19980420
PRIORITY APPLN. INFO.:			GB 1997-8092	A 19970422
			WO 1998-GB1144	W 19980420

AB **Mdm2** binds to **p53** in cells in which **mdm2** is not overexpressed, i.e. in cells in which **mdm2** is expressed at normal or low levels, and that in these cells, this interaction targets the **p53** for degradation. This finding means that inhibiting **mdm2** production and/or inhibiting the binding of **mdm2** to **p53** allows levels of **p53** to increase by reducing the clearance of **p53** by **mdm2**, and can be used to activate **p53** function in cells other than those in which **mdm2** is overexpressed. This allows the use of an agent having the property of disrupting the binding of **p53** and **mdm2** or inhibiting the production of **mdm2** in a population of cells, in the preparation of a medicament for activating **p53**, wherein the population of cells do not overexpress **mdm2**. Such medicaments are useful in the treatment of conditions such as cancer, viral infections or conditions in which **p53** or **mdm2** is not functional. Peptide aptamer inserts into thioredoxin created potent inhibitors of the **p53-mdm2** interaction.

IT 215295-80-0
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (peptide aptamer insert TIP 12/1; agents and methods for inhibiting **p53-mdm2** interaction, and use for treatment of cancer, viral infections, or other conditions, and screening method)

09/214371

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Feb 1998
ACCESSION NUMBER: 1998:65923 CAPLUS
DOCUMENT NUMBER: 128:128291
TITLE: Preparation of compounds (peptides) capable of binding to MDM2 for inhibition of the binding of MDM2 to p53 protein
INVENTOR(S): Lane, David; Bottger, Volker; Bottger, Angelika; Picksley, Stephen; Hochkeppel, Heinz-Kurt; Garcia-Echeverria, Carlos; Chene, Patrick; Furet, Pascal
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Cancer Research Campaign Technology Ltd.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9801467	A2	19980115	WO 1997-EP3549	19970704
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2259149	AA	19980115	CA 1997-2259149	19970704
AU 9738479	A1	19980202	AU 1997-38479	19970704
EP 958305	A2	19991124	EP 1997-935511	19970704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
NZ 333609	A	20000825	NZ 1997-333609	19970704
JP 2001500365	T2	20010116	JP 1998-504775	19970704
US 2001018511	A1	20010830	US 1999-214371	19990326
AU 777766	B2	20041028	AU 2001-14979	20010115
AU 2001014979	A5	20011206		
US 2005137137	A1	20050623	US 2004-927262	20040825
PRIORITY APPLN. INFO.:			GB 1996-14197	A 19960705
			GB 1997-7041	A 19970407
			AU 1997-38479	A3 19970704
			WO 1997-EP3549	W 19970704
			US 1999-214371	A1 19990326

OTHER SOURCE(S): MARPAT 128:128291
AB The present invention relates to compds. capable of binding to the

09/214371

oncogene protein **MDM2**, processes for the preparation of such compds., pharmaceutical preps. comprising such compds., and uses of said compds., e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body (no data given). The title compds. R1XFXR2R3WXXR4 (R1 = Pro, Leu, Glu, Cys, Gln; X = natural amino acid; F = Phe; R2 = Arg, His, Glu, Cys, Ser, preferably Asp; R3 = His, Phe, preferably Tyr; W = Trp; R4 = Phe, Gln, preferably Leu) and their derivs. were prepared on Milligen 9050 automated peptide synthesizer by using the standard Boc and Fmoc chemical

IT 201984-20-5P 201984-22-7P 201984-41-0P
201984-43-2P 201984-45-4P 201984-47-6P
201984-49-8P 201984-68-1P 201984-97-6P
201984-98-7P 202075-45-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides as inhibitors of the binding interaction between **MDM2** and protein **p53**)

L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 23 Dec 1996

ACCESSION NUMBER: 1996:752178 CAPLUS

DOCUMENT NUMBER: 126:112803

TITLE: Identification of novel **mdm2** binding peptides by phage display

AUTHOR(S): Bottger, Volker; Bottger, Angelika; Howard, Stephanie F.; Picksley, Steven M.; Chene, Patrick; Garcia-Echeverria, Carlos; Hochkeppel, Heinz-Kurt; Lane, David P.

CORPORATE SOURCE: Cancer Res. Campaign Lab., Univ. Dundee, Dundee, DD1 4HN, UK

SOURCE: Oncogene (1996), 13(10), 2141-2147

CODEN: ONCNES; ISSN: 0950-9232

PUBLISHER: Stockton

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The oncogene **mdm2** and its human homolog **hdm2** bind to the tumor suppressor protein **p53** and inactivate its function as a transcription factor. This has been implied as a possible mechanism for cancer development in several tumors including human sarcomas. The **mdm2-p53** interaction is therefore a much pursued target for the development of anti-cancer drugs. In order to find novel high affinity ligands for **hdm2** which would interfere with its binding to **p53** we screened phage display peptide libraries for **mdm2** binding phage. We found a series of 12 and 15mer peptides which interact strongly with **hdm2**. The peptide sequences show striking homol. with the previously established **mdm2** binding site on **p53**, confirming that the peptide defined 18TFSDLW23 region is crucial for the interaction but that contact between the two mols. extends to position L26 on **p53**. Free synthetic peptides derived from the phage selected sequences proved to be up to 100 times stronger inhibitors of the **p53-mdm2** interaction than the **p53** derived wt-peptide in several ELISA-assays. This illustrates the potency of phage display libraries in the search for new peptide based lead structures designed to mimic or inhibit therapeutically important protein-protein interactions.

IT 186180-20-1P 186180-22-3P 186180-23-4P

09/214371

186180-24-5P 186180-25-6P

RL: BAC (Biological activity or effector, except adverse); BPN
(Biosynthetic preparation); BSU (Biological study, unclassified); BIOL
(Biological study); PREP (Preparation)
(identification of novel **mdm2** binding peptides by phage
display)

E1 THROUGH E28 ASSIGNED

FILE 'REGISTRY' ENTERED AT 12:14:32 ON 19 OCT 2005

L4 28 SEA FILE=REGISTRY ABB=ON PLU=ON (186180-20-1/BI OR
186180-22-3/BI OR 186180-23-4/BI OR 186180-24-5/BI OR
186180-25-6/BI OR 201984-98-7/BI OR 391966-46-4/BI OR
201984-21-6/BI OR 215295-80-0/BI OR 393113-21-8/BI OR
201984-20-5/BI OR 201984-22-7/BI OR 201984-41-0/BI OR
201984-43-2/BI OR 201984-45-4/BI OR 201984-47-6/BI OR
201984-49-8/BI OR 201984-68-1/BI OR 201984-97-6/BI OR
202075-45-4/BI OR 227200-18-2/BI OR 393113-19-4/BI OR
393113-22-9/BI OR 393113-23-0/BI OR 393113-24-1/BI OR
393113-25-2/BI OR 595567-95-6/BI OR 786732-92-1/BI)

L5 28 L1 AND L4

L5 ANSWER 1 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN **786732-92-1** REGISTRY

CN Growth hormone receptor (human clone DE10316701-SEQID-503 gene GHR)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 113: PN: DE10316701 PAGE: 1214 claimed sequence

CI MAN

SQL 638

SEQ 1 MDLWQLLLTL ALAGSSDAFS GSEATAAILS RAPWSLQSVN PGLKTNSSKE
51 PKFTKCRSPE RETFSCHWTD EVHHGTKNLG PIQLFYTRRN TQQWTQEWEKE

===== =

101 CPDYVSAGEN SCYFNSSFTS IWIPYCIKLT SNGGTVDK FSVDEIVQPD
151 PPIALNWTLV NVSLTGIHAD IQVRWEAPRN ADIQKGWMVL EYELQYKEVN
201 ETKWKMMDP I LTTSPVYSL KVDKEYEV RV RSKQRNSGNY GEFSEVLYVT
251 LPQMSQFTCE EDFYFPWLII IIFGIFGLTV MLFVFLFSKQ QRIKMLILPP
301 VPVPKIKGID PDLLKEGKLE EVNTILAIHD SYKPEFHSD SWVEFIELDI
351 DEPDEKTEES DTDRLLSSDH EKSHSNLGVK DGDSGRTSCC EPDILETDFN
401 ANDIHEGTSE VAQPQRLKGE ADLLCLDQKN QNNSPYHDAC PATQQPSVIQ
451 AEKNKPQPLP TEGAESTHQA AHIQLSNPSS LSNIDFYAQV SDITPAGSVV
501 LSPGQKNKAG MSQCDMHPEM VSLCQENFLM DNAYFCEADA KKCIPIVAPHI
551 KVESHIQPSL NQEDIYITTE SLTTAAGRPG TGEHVPGSEM PVPDYTSIHI
601 VQSPQGLILN ATALPLPDKE FLSSCGYVST DQLNKIMP

HITS AT: 64-71

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:393465

L5 ANSWER 2 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN **595567-95-6** REGISTRY

CN L-Leucine, L-methionyl-L-prolyl-L-arginyl-L-phenylalanyl-L-methionyl-L-
α-aspartyl-L-tyrosyl-L-tryptophyl-L-α-glutamyl-L-α-
aspartyl- (9CI) (CA INDEX NAME)

SQL 11

09/214371

SEQ 1 MPRFMDYWED L
=====

HITS AT: 4-11

REFERENCE 1: 139:226753

L5 ANSWER 3 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 393113-25-2 REGISTRY
CN L-Asparagine, L-proyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
SQL 11

SEQ 1 PRFMDYWEGL N
=====

HITS AT: 3-10

REFERENCE 1: 136:128583

L5 ANSWER 4 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 393113-24-1 REGISTRY
CN L-Asparagine, L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
SQL 10

SEQ 1 RFMDYWEGLN
=====

HITS AT: 2-9

REFERENCE 1: 136:128583

L5 ANSWER 5 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 393113-23-0 REGISTRY
CN L-Leucine, L-proyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl- (9CI) (CA INDEX NAME)
SQL 10

SEQ 1 PRFMDYWEGL
=====

HITS AT: 3-10

REFERENCE 1: 136:128583

L5 ANSWER 6 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 393113-22-9 REGISTRY
CN L-Asparagine, L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
SQL 9

SEQ 1 FMDYWEGLN
=====

HITS AT: 1-8

REFERENCE 1: 136:128583

L5 ANSWER 7 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 393113-21-8 REGISTRY

Searcher : Shears 571-272-2528

09/214371

CN L-Leucine, L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2: PN: WO03095625 SEQID: 2 unclaimed protein
SQL 9

SEQ 1 RFMDYWEGL
=====

HITS AT: 2-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:776

REFERENCE 2: 136:128583

L5 ANSWER 8 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 393113-19-4 REGISTRY

CN L-Leucine, L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl- (9CI) (CA INDEX NAME)

SQL 8

SEQ 1 FMDYWEGL
=====

HITS AT: 1-8

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:128583

L5 ANSWER 9 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 391966-46-4 REGISTRY

CN Protein (human clone ghr.262, ghr.210, ghr.501, ghr.110, ghr.281 638-amino acid) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2963: PN: WO03091391 TABLE: 20 unclaimed protein

CN 694: PN: WO03010336 TABLE: 2A claimed protein

CN 87: PN: WO2004108964 PAGE: 36 claimed protein

CN GenBank CAA29808

CN GenBank CAA29808 (Translated from: GenBank X06562)

CI MAN

SQL 638

SEQ 1 MDLWQLLLTL ALAGSSDAFS GSEATAAILS RAPWSLQSVN PGLKTNSSKE
51 PKFTKCRSPE RETFSCHWTD EVHHGTKNLG PIQLFYTRRN TQEWTQEWEKE
=====

101 CPDYVSAGEN SCYFNSSFTS IWIPYCIKLT SNGGTVDK FSVDEIVQPD
151 PPIALNWTLI NVSLTGIHAD IQVRWEAPRN ADIQKGWMVL EYELQYKEVN
201 ETKWKMMDP I LTTSPVYSL KVDKEYEV RV RSKQRNSGN Y GEFSEVLYVT
251 LPQMSQFTCE EDFYFPWLLI IIFGIFGLTV MLFVFLFSKQ QRIKMLILPP
301 VPVPKIKGID PDLLKEGKLE EVNTILAIHD SYKPEFHSD SWVEFIELDI
351 DEPDEKTEES DTDRLLSSDH EKSHSNLGVK DGDSGRTSCC EPDILETDFN
401 ANDIHEGTSE VAQPQRLKGE ADLLCLDQKN QNNSPYHDAC PATQQPSVIQ
451 AEKNKPQPLP TEGAESTHQA AHIQLSNPSS LSNIDFYAQV SDITPAGSVV
501 LSPGQKNAKAG MSQCDMHPEM VSLCQENFLM DNAYFCEADA KKCIIPVAPHI
551 KVESHIQPSL NQEDIYITTE SLTTAACRPG TGEHVPGSEM PVPDYTSIHI
601 VQSPQGLILN ATALPLPDKE FLSSCGYVST DQLNKIMP

HITS AT: 64-71

09/214371

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 142:69928

REFERENCE 2: 140:3792

REFERENCE 3: 138:164674

REFERENCE 4: 136:146104

L5 ANSWER 10 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 227200-18-2 REGISTRY

CN L-Asparagine, L-methionyl-L-prolyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl-L-asparaginylglycyl-L-prolylglycyl-L-methionyl-L-prolyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

SQL 27

SEQ 1 MPRFMDYWEG LNGPGMPRFM DYWEGLN
===== = == =====

HITS AT: 4-11, 19-26

REFERENCE 1: 131:42875

L5 ANSWER 11 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 215295-80-0 REGISTRY

CN Glycine, L-prolyl-L-prolyl-L-leucyl-L-seryl-L-methionyl-L-prolyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl-L-asparaginyl-L- α -glutamyl-L-asparaginyl- (9CI) (CA INDEX NAME)

SQL 19

SEQ 1 PPLSMPRFMD YWEGLNENG
==== =====

HITS AT: 8-15

REFERENCE 1: 129:326112

REFERENCE 2: 129:326111

L5 ANSWER 12 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 202075-45-4 REGISTRY

CN L-Lysinamide, N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-seryl-L-methionyl-L-prolyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl-L-asparaginyl-L-arginyl-L-glutaminyl-L-isoleucyl-L-lysyl-L-isoleucyl-L-tryptophyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-arginyl-L-arginyl-L-methionyl-L-lysyl-L-tryptophyl-L-lysyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

SQL 29

SEQ 1 SMPRFMDYWE GLNRQIKIWF QNRRMKWKK
===== ==

HITS AT: 5-12

REFERENCE 1: 128:128291

09/214371

L5 ANSWER 13 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 201984-98-7 REGISTRY
CN L-Leucinamide, N-acetyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl- (9CI) (CA INDEX NAME)
SQL 8

SEQ 1 FMDYWEGL
=====

HITS AT: 1-8

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:52744

REFERENCE 2: 133:246812

REFERENCE 3: 128:128291

L5 ANSWER 14 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 201984-97-6 REGISTRY
CN L-Leucinamide, N2-acetyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)
SQL 9

SEQ 1 RFMDYWEGL
=====

HITS AT: 2-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 128:128291

L5 ANSWER 15 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 201984-68-1 REGISTRY
CN L-Lysinamide, N-acetyl-L-alanyl-L-alanyl-L-valyl-L-alanyl-L-leucyl-L-leucyl-L-prolyl-L-alanyl-L-valyl-L-leucyl-L-leucyl-L-alanyl-L-prolyl- β -alanyl-L-methionyl-L-prolyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl-L-asparaginyl- β -alanyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)
SQL 31

SEQ 1 AAVALLPAVL LALLAPXMPR FMDYWEGLNK K
=====

HITS AT: 21-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 128:128291

L5 ANSWER 16 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 201984-49-8 REGISTRY
CN L-Aspartamide, L-methionyl-L-prolyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

09/214371

SQL 12

SEQ 1 MPRFMDYWEG LN
===== =

HITS AT: 4-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 128:128291

L5 ANSWER 17 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 201984-47-6 REGISTRY
CN L-Phenylalaninamide, L-threonylglycyl-L-prolyl-L-alanyl-L-phenylalanyl-L-threonyl-L-histidyl-L-tyrosyl-L-tryptophyl-L-alanyl-L-threonyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

SQL 12

SEQ 1 TGPAFTHYWA TF
===== ==

HITS AT: 5-12

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 128:128291

L5 ANSWER 18 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 201984-45-4 REGISTRY
CN L-Histidinamide, 1-acetyl-L-prolyl-L-alanyl-L-phenylalanyl-L-seryl-L-arginyl-L-phenylalanyl-L-tryptophyl-L-seryl-L- α -aspartyl-L-leucyl-L-seryl-L-alanylglucyl-L-alanyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

SQL 15

SEQ 1 PAFSRFWSDL SAGAH
=====

HITS AT: 3-10

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 128:128291

L5 ANSWER 19 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 201984-43-2 REGISTRY
CN L-Tyrosinamide, 1-acetyl-L-prolyl-L-arginyl-L-prolyl-L-alanyl-L-leucyl-L-valyl-L-phenylalanyl-L-alanyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamyl-L-threonyl-L-leucyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

SQL 15

SEQ 1 PRPALVFADY WETLY
===== =====

HITS AT: 7-14

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 128:128291

L5 ANSWER 20 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 201984-41-0 REGISTRY

Searcher : Shears 571-272-2528

09/214371

CN L-Valinamide, N-acetyl-L-isoleucyl-L- α -aspartyl-L-arginyl-L-alanyl-L-prolyl-L-threonyl-L-phenylalanyl-L-arginyl-L- α -aspartyl-L-histidyl-L-tryptophyl-L-phenylalanyl-L-alanyl-L-leucyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

SQL 15

SEQ 1 IDRAPTFRDH WFALV
=====

HITS AT: 7-14

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 128:128291

L5 ANSWER 21 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 201984-22-7 REGISTRY

CN L-Aspartamide, N-acetyl-L-methionyl-L-prolyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

SQL 12

SEQ 1 MPRFMDYWEG LN
===== =

HITS AT: 4-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 128:128291

L5 ANSWER 22 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 201984-21-6 REGISTRY

CN L-Aspartamide, N-acetyl-L-methionyl-L-prolyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

CI COM

SQL 12

SEQ 1 MPRFMDYWEG LN
===== =

HITS AT: 4-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:52744

REFERENCE 2: 133:246812

L5 ANSWER 23 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 201984-20-5 REGISTRY

CN L-Phenylalaninamide, N-acetyl-L-threonylglycyl-L-prolyl-L-alanyl-L-phenylalanyl-L-threonyl-L-histidyl-L-tyrosyl-L-tryptophyl-L-alanyl-L-threonyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

SQL 12

SEQ 1 TGPAFTHYWA TF
===== ==

HITS AT: 5-12

09/214371

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 128:128291

L5 ANSWER 24 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 186180-25-6 REGISTRY
CN L-Histidine, L-proyl-L-alanyl-L-phenylalanyl-L-seryl-L-arginyl-L-phenylalanyl-L-tryptophyl-L-seryl-L- α -aspartyl-L-leucyl-L-seryl-L-alanylglucyl-L-alanyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 107: PN: WO0024782 SEQID: 140 claimed sequence
CN 623: PN: WO03084477 PAGE: 45 claimed sequence
CN 636: PN: WO2004002417 SEQID: 787 claimed sequence
CN 663: PN: WO2004002424 SEQID: 787 claimed sequence
CN 725: PN: WO0183525 TABLE: 13 claimed protein
SQL 15

SEQ 1 PAFSRFWSDL SAGAH
=====

HITS AT: 3-10

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:110119

REFERENCE 2: 140:110118

REFERENCE 3: 139:322283

REFERENCE 4: 135:366701

REFERENCE 5: 132:329919

REFERENCE 6: 126:112803

L5 ANSWER 25 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN
RN 186180-24-5 REGISTRY
CN L-Tyrosine, L-proyl-L-arginyl-L-proyl-L-alanyl-L-leucyl-L-valyl-L-phenylalanyl-L-alanyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamyl-L-threonyl-L-leucyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 106: PN: WO0024782 SEQID: 139 claimed sequence
CN 622: PN: WO03084477 PAGE: 45 claimed sequence
CN 635: PN: WO2004002417 SEQID: 786 claimed sequence
CN 662: PN: WO2004002424 SEQID: 786 claimed sequence
CN 724: PN: WO0183525 TABLE: 13 claimed protein
SQL 15

SEQ 1 PRPALVFADY WETLY
===== =====

HITS AT: 7-14

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:110119

REFERENCE 2: 140:110118

REFERENCE 3: 139:322283

09/214371

REFERENCE 4: 135:366701

REFERENCE 5: 132:329919

REFERENCE 6: 126:112803

L5 ANSWER 26 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 186180-23-4 REGISTRY

CN L-Valine, L-isoleucyl-L- α -aspartyl-L-arginyl-L-alanyl-L-prolyl-L-threonyl-L-phenylalanyl-L-arginyl-L- α -aspartyl-L-histidyl-L-tryptophyl-L-phenylalanyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 105: PN: WO0024782 SEQID: 138 claimed sequence

CN 621: PN: WO03084477 PAGE: 45 claimed sequence

CN 634: PN: WO2004002417 SEQID: 785 claimed sequence

CN 661: PN: WO2004002424 SEQID: 785 claimed sequence

CN 723: PN: WO0183525 TABLE: 13 claimed protein

SQL 15

SEQ 1 IDRAPTFRDH WFALV
=====

HITS AT: 7-14

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:110119

REFERENCE 2: 140:110118

REFERENCE 3: 139:322283

REFERENCE 4: 135:366701

REFERENCE 5: 132:329919

REFERENCE 6: 126:112803

L5 ANSWER 27 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 186180-22-3 REGISTRY

CN L-Phenylalanine, L-threonylglycyl-L-prolyl-L-alanyl-L-phenylalanyl-L-threonyl-L-histidyl-L-tyrosyl-L-tryptophyl-L-alanyl-L-threonyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 104: PN: WO0024782 SEQID: 137 claimed sequence

CN 620: PN: WO03084477 PAGE: 45 claimed sequence

CN 633: PN: WO2004002417 SEQID: 784 claimed sequence

CN 660: PN: WO2004002424 SEQID: 784 claimed sequence

CN 722: PN: WO0183525 TABLE: 13 claimed protein

SQL 12

SEQ 1 TGPAFTHYWA TF
=====

HITS AT: 5-12

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:110119

09/214371

REFERENCE 2: 140:110118

REFERENCE 3: 139:322283

REFERENCE 4: 135:366701

REFERENCE 5: 132:329919

REFERENCE 6: 126:112803

L5 ANSWER 28 OF 28 REGISTRY COPYRIGHT 2005 ACS on STN

RN 186180-20-1 REGISTRY

CN L-Asparagine, L-methionyl-L-prolyl-L-arginyl-L-phenylalanyl-L-methionyl-L- α -aspartyl-L-tyrosyl-L-tryptophyl-L- α -glutamylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 102: PN: WO0024782 SEQID: 135 claimed sequence

CN 1: PN: WO03095625 SEQID: 1 unclaimed protein

CN 618: PN: WO03084477 PAGE: 45 claimed sequence

CN 631: PN: WO2004002417 SEQID: 782 claimed sequence

CN 658: PN: WO2004002424 SEQID: 782 claimed sequence

CN 720: PN: WO0183525 TABLE: 13 claimed protein

SQL 12

SEQ 1 MPRFMDYWEG LN

===== =

HITS AT: 4-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:110119

REFERENCE 2: 140:110118

REFERENCE 3: 140:776

REFERENCE 4: 139:322283

REFERENCE 5: 135:366701

REFERENCE 6: 132:329919

REFERENCE 7: 131:42875

REFERENCE 8: 126:112803

FILE 'MEDLINE' ENTERED AT 12:15:06 ON 19 OCT 2005

FILE 'BIOSIS' ENTERED AT 12:15:06 ON 19 OCT 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:15:06 ON 19 OCT 2005

Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 12:15:06 ON 19 OCT 2005

L6 0 L4

=> fil hom

09/214371

FILE 'HOME' ENTERED AT 12:15:15 ON 19 OCT 2005

Searcher : Shears 571-272-2528

09/214371

=> d his ful

(FILE 'HOME' ENTERED AT 12:10:19 ON 19 OCT 2005)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:11:34 ON 19 OCT 2005
L1 164 SEA ABB=ON PLU=ON F[MITRAS].[RHECSD].[HFY]W[ETASF].[GQTAD].[F
EL]/SQSP

FILE 'CAPLUS' ENTERED AT 12:11:42 ON 19 OCT 2005
L2 96 SEA ABB=ON PLU=ON L1
L*** DEL 2 S BOTTGER ?/AU AND L2
D TI AU 1-2
D .BEVSTR1
L3 16 SEA ABB=ON PLU=ON L2 AND (MDM# OR P53)
D KWIC

FILE 'REGISTRY' ENTERED AT 12:14:03 ON 19 OCT 2005
D QUE L1

FILE 'CAPLUS' ENTERED AT 12:14:03 ON 19 OCT 2005
D 1-16 .BEVSTR
SEL HIT L3 1-16 RN

FILE 'REGISTRY' ENTERED AT 12:14:32 ON 19 OCT 2005
L4 28 SEA ABB=ON PLU=ON (186180-20-1/BI OR 186180-22-3/BI OR
186180-23-4/BI OR 186180-24-5/BI OR 186180-25-6/BI OR
201984-98-7/BI OR 391966-46-4/BI OR 201984-21-6/BI OR
215295-80-0/BI OR 393113-21-8/BI OR 201984-20-5/BI OR
201984-22-7/BI OR 201984-41-0/BI OR 201984-43-2/BI OR
201984-45-4/BI OR 201984-47-6/BI OR 201984-49-8/BI OR
201984-68-1/BI OR 201984-97-6/BI OR 202075-45-4/BI OR
227200-18-2/BI OR 393113-19-4/BI OR 393113-22-9/BI OR
393113-23-0/BI OR 393113-24-1/BI OR 393113-25-2/BI OR
595567-95-6/BI OR 786732-92-1/BI)
D QUE

L5 28 SEA ABB=ON PLU=ON L1 AND L4
D L5 1-28 .BEVREG1

FILE 'MEDLINE, BIOSIS, EMBASE, CANCERLIT' ENTERED AT 12:15:06 ON 19
OCT 2005

L6 0 SEA ABB=ON PLU=ON L4

FILE 'HOME' ENTERED AT 12:15:15 ON 19 OCT 2005

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 OCT 2005 HIGHEST RN 865529-02-8
DICTIONARY FILE UPDATES: 18 OCT 2005 HIGHEST RN 865529-02-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Searcher : Shears 571-272-2528

09/214371

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMI for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Oct 2005 VOL 143 ISS 17
FILE LAST UPDATED: 18 Oct 2005 (20051018/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE MEDLINE

FILE LAST UPDATED: 18 OCT 2005 (20051018/UP). FILE COVERS 1950 TO DA

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate

Searcher : Shears 571-272-2528

09/214371

substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 12 October 2005 (20051012/ED)

FILE RELOADED: 19 October 2003.

FILE EMBASE

FILE COVERS 1974 TO 13 Oct 2005 (20051013/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE CANCERLIT

FILE COVERS 1963 TO 15 Nov 2002 (20021115/ED)

On July 28, 2002, CANCERLIT was reloaded. See HELP RLOAD for details

CANCERLIT thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

This file contains CAS Registry Numbers for easy and accurate substan
identification.